tbuckley/cabot-search huggingface dataset:
Permanent Pacemaker Implantation After Transcatheter Aortic Valve Implantation
Authors: Marina Urena, John G. Webb, Corrado Tamburino, Antonio J. Muñoz-García, Asim Cheema, Antonio E. Dager, Vicenç Serra, Ignacio J. Amat-Santos, Marco Barbanti, Sebastiano Immè, Juan H. Alonso Briales, Luis Miguel Benitez, Hatim Al Lawati, Angela Maria Cucalon, Bruno García del Blanco, Javier López, Eric Dumont, Robert DeLarochellière, Henrique B. Ribeiro, Luis Nombela-Franco, François Philippon, Josep Rodés-Cabau
Journal: Circulation (2013)

Background— Very few data exist on the clinical impact of permanent pacemaker implantation (PPI) after transcatheter aortic valve implantation. The objective of this study was to assess the impact of PPI after transcatheter aortic valve implantation on late outcomes in a large cohort of patients. Methods and Results— A total of 1556 consecutive patients without prior PPI undergoing transcatheter aortic valve implantation were included. Of them, 239 patients (15.4%) required a PPI within the first 30 days after transcatheter aortic valve implantation. At a mean follow-up of 22±17 months, no association was observed between the need for 30-day PPI and all-cause mortality (hazard ratio, 0.98; 95% confidence interval, 0.74–1.30; P =0.871), cardiovascular mortality (hazard ratio, 0.81; 95% confidence interval, 0.56–1.17; P =0.270), and all-cause mortality or rehospitalization for heart failure (hazard ratio, 1.00; 95% confidence interval, 0.77–1.30; P =0.980). A lower rate of unexpected (sudden or unknown) death was observed in patients with PPI (hazard ratio, 0.31; 95% confidence interval, 0.11–0.85; P =0.023). Patients with new PPI showed a poorer evolution of left ventricular ejection fraction over time ( P =0.017), and new PPI was an independent predictor of left ventricular ejection fraction decrease at the 6- to 12-month follow-up (estimated coefficient, −2.26; 95% confidence interval, −4.07 to −0.44; P =0.013; R 2 =0.121). Conclusions— The need for PPI was a frequent complication of transcatheter aortic valve implantation, but it was not associated with any increase in overall or cardiovascular death or rehospitalization for heart failure after a mean follow-up of ≈2 years. Indeed, 30-day PPI was a protective factor for the occurrence of unexpected (sudden or unknown) death. However, new PPI did have a negative effect on left ventricular function over time.
Abstract IA13: Ribosome stalling and disease
Authors: Susan L. Ackerman
Journal: Cancer Research (2017)

Abstract La Jolla, CA. Protein synthesis is vital for cell function and disturbances in translation are associated with cancer, neurological disorders and other diseases. Although regulation of translation is thought to largely occur at initiation, elongation, the reiterative addition of amino acids by the ribosome, is emerging as a translational phase that is also highly regulated. Transfer RNAs, the adaptor molecules essential for elongation are encoded by several hundreds of nuclear genes in higher eukaryotes suggesting great functional redundancy. Our work has defined epistatic interactions between mutations in a mammalian tRNA gene and a novel ribosome rescue factor, defining the importance of individual tRNA genes in translation and the pathologies that can arise from disruptions in this process. Citation Format: Susan L. Ackerman. Ribosome stalling and disease. [abstract]. In: Proceedings of the AACR Special Conference on Translational Control of Cancer: A New Frontier in Cancer Biology and Therapy; 2016 Oct 27-30; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2017;77(6 Suppl):Abstract nr IA13.
Validation of the 2016 Revision to the World Health Organization (WHO) Classification of Myelodysplastic Syndromes with Diploid Karyotype
Authors: Rashmi Kanagal-Shamanna, Juliana E. Hidalgo Lopez, Hye Ryoun Kim, Zhuang Zuo, Michelle Janania Martinez, Chong Zhao, Denái R. Milton, Francesco Stingo, John Lee, Raja Luthra, Keyur P. Patel, Elias J. Jabbour, Guillermo Garcia-Manero, L. Jeffrey Medeiros, Carlos E Bueso-Ramos
Journal: Blood (2016)
Elevated serum wisteria floribunda agglutinin-positive mac-2-binding protein levels associated with risks of diabetes and endstage renal diseases among patients with hepatitis C virus infection
Authors: Y.-J. Lin, C.-L. Chang, L.-C. Chen, H.-H. Hu, J. Liu, M. Korenaga, Y.-H. Huang, S.-Y. Chan, C.-L. Jen, C.-Y. Su, S.-N. Lu, L.-Y. Wang, Y. Yuan, M. Mizokami, C.-J. Chen, H.-I. Yang, M.-H. Lee
Journal: Journal of Hepatology (2017)
Towards clinical use of targeted therapies for liver fibrosis: development of a sustained release formulation for therapeutic proteins
Authors: F. Van Dijk, N. Teekamp, L. Beljaars, E. Post, D. Schuppan, Y.O. Kim, K. Poelstra, E. Frijlink, W. Hinrichs, P. Olinga
Journal: Journal of Hepatology (2017)
Etirinotecan pegol (EP) target-specific pharmacodynamic (PD) biomarkers measured in circulating tumor cells (CTCs) from patients in the phase III BEACON study in patients with metastatic breast cancer (mBC).
Authors: Ute Hoch, Dennis G. Fry, Yen Lin Chia, Katie Caygill, Alison L. Hannah, Edith A. Perez, Javier Cortez, Ahmad Awada, Joyce O'Shaughnessy, Christopher Twelves, Hope S. Rugo, Seock-Ah Im, Binghe Xu, Kenna Lynn Anderes, Darren W. Davis
Journal: Journal of Clinical Oncology (2013)

1087 Background: EP is a unique topoisomerase 1 inhibitor that provides continuous exposure to SN38. EP demonstrated a 29% overall response rate in patients with mBC, leading to a phase III global BEACON study in patients with mBC. CTCs in patient blood samples provide a minimally invasive approach to detect PD markers of drug activity. We developed quantitative multiplex immunofluorescent assays to measure target-specific PD biomarkers for EP in CTCs isolated pre- and post-treatment. Methods: Assays for Top1, Top2, g-H2Ax, Rad51, ABCG2, and Ki-67 were developed using control (0.1% DMSO) and drug-treated (SN38, 10 uM) tumor cell lines (HCT116, MCF7, A549, SKBr3) and PBMCs from healthy donors. The optimal antibody for each biomarker was then multiplexed in a panel with antibodies against cytokeratin, CD45 and DAPI for phenotypic identification of CTCs. For analysis of BEACON pts, serial 7.5 mL whole blood samples were drawn and shipped ambient to Apocell (Houston, TX) for further processing. PBMCs were separated and CTCs were isolated using ApoStream technology. CTCs were stained for PD markers and analyzed using an iCys laser scanning cytometer equipped with image analysis software. Results: Antibodies bound to tumor cells showed staining confined to the nucleus (Top1, Top2, g-H2AX, Ki-67) or membrane (ABCG2), exhibited defined peak separation from their isotype controls, and signal strength correlated with cellular expression of high and low levels of markers. To date, ~ 80% of BEACON pts consent to participate in the CTC sub-study. As of 30 Oct 2012, data from 167 pre-dose blood samples from BEACON pts were available. 99% of blood samples were successfully processed. 93% had detectable CTCs, yielding a median of 216 CTCs (range: 7.5-14816). Staining was positive for Top1, Top2, g-H2Ax, Rad51, ABCG2, and Ki-67 in 82%, 89%, 16%, 53%, 31%, 52% of samples, respectively. Conclusions: EP target-specific pharmacodynamic biomarkers can be reliably measured in CTCs isolated from patients participating in BEACON. Sample collection and analysis of pre- and post-treatment samples is ongoing. Clinical trial information: NCT01492101.
A phase II single-arm pilot study of second-line icotinib treatment in advanced esophageal cancer with EGFR over-expression or amplification.
Authors: Jing Huang, Qingxia Fan, Ping Lu, Jianming Ying, Changwu Ma, Wei Liu, Junfeng Liu, Ying Liu, Fenlai Tan, Yan Sun
Journal: Journal of Clinical Oncology (2015)

4044 Background: Epidermal growth factor receptor (EGFR) has been reported to be overexpressed in esophageal cancer, suggesting EGFR-directed treatment is a potential option. Here we report the antitumor activities of icotinib, a selective EGFR tyrosine kinase inhibitor (TKI), as second-line treatment for advanced esophageal cancer with EGFR over-expression or amplification. Methods: In this phase II, single-arm study, eligible patients were adults with advanced esophageal cancer confirmed by histology, who had received at least first-line chemotherapy, with EGFR over-expression [immunohistochemistry (IHC), 3+] or amplification [positive fluorescence in-situ hybridisation (FISH)]. Participants were treated with oral icotinib (250 mg, three times daily).The primary endpoint was objective response rate (ORR). Results: Between December, 2013 and January, 2015, 38 patients were enrolled (37 with squamous cell carcinoma, 1 with adenocarcinoma) with a median age of 60, in which 36 were IHC 3+ (94.7%) and 2 were IHC 2+ with positive FISH. And as of the December 31, 2014 cutoff, 33 patients were evaluable for response. The ORR was 15.2% (5/33), consisting of 1 CR and 4 PRs, and the disease control rate was 54.5% (18/33). The median duration of treatment in 18 patients (CR + PR + SD) is 12.3 weeks with the longest being 28+ weeks. Twenty-three out of 33 patients (69.7%) experienced at least one adverse event (AE) with rash (42.4%), diarrhea (24.2%), pain (21.2%), fatigue (15.2%) and vomiting (12.1%) as the most common ones. Most AEs were mild and reversible and no grade 3 or 4 AEs were reported. Conclusions: Second-line icotinib treatment in advanced esophageal cancer with EGFR over-expression or amplification demonstrated favorable outcome along with a high safety profile. However, the role of EGFR over-expression or amplification as predictive biomarker still needs further exploration. Clinical trial information: NCT01855854. Clinical trial information: NCT01855854..
One year follow-up and HBV RNA / HBcrAg analysis in the REP 301 Trial: REP 2139 and pegylated interferon alpha-2a in Caucasian patients with chronic HBV / HDV co-infection
Authors: M. Bazinet, V. Pantea, V. Cebotarescu, L. Cojuhari, P. Jimbei, A. Krawczyk, A. Vaillant
Journal: Journal of Hepatology (2017)
NIAID, NIEHS, NHLBI, and MCAN Workshop Report: The indoor environment and childhood asthma—implications for home environmental intervention in asthma prevention and management
Authors: Diane R. Gold, Gary Adamkiewicz, Syed Hasan Arshad, Juan C. Celedón, Martin D. Chapman, Ginger L. Chew, Donald N. Cook, Adnan Custovic, Ulrike Gehring, James E. Gern, Christine C. Johnson, Suzanne Kennedy, Petros Koutrakis, Brian Leaderer, Herman Mitchell, Augusto A. Litonjua, Geoffrey A. Mueller, George T. O'Connor, Dennis Ownby, Wanda Phipatanakul, Victoria Persky, Matthew S. Perzanowski, Clare D. Ramsey, Päivi M. Salo, Julie M. Schwaninger, Joanne E. Sordillo, Avrum Spira, Shakira F. Suglia, Alkis Togias, Darryl C. Zeldin, Elizabeth C. Matsui
Journal: Journal of Allergy and Clinical Immunology (2017)
Of Wine Stains and Vases—William Allen Sturge’s Diverse Legacy
Authors: Raghav Gupta, Katrice Karanfilian, Ahmed Kashkoush, Arpan V. Prabhu, Thomas G. Benedek
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Reduced-intensity cord blood transplantation following a regimen using fludarabine and busulfan in adult patients with advanced hematologic malignancies.
Authors: Naoko Takei, Kenji Tsuda, Tatsuo Itokawa, Takahiro Isshiki, Yuji Satou, Masae Kurama, Tsunehiko Komatsu
Journal: Journal of Clinical Oncology (2014)

7036 Background: Cord blood transplantation has grown as an effective alternative therapy for treating patients with advanced or high-risk hematologic malignancies who have no suitable related or unrelated donor. We report the results of reduced-intensity cord blood transplantation (RI-CBT) following a regimen using fludarabine and busulfan in adult patients with advanced hematologic malignancies. Methods: 45 patients (median age, 62 years; range, 26-74 years) underwent RI-CBT at Teikyo University Chiba Medical Center and Tsukuba Memorial Hospital between April 2004 and November 2013. Preparative regimens consisted of fludarabine 30 mg/m2 for 6 days and busulfan 0.8 mg/kg x 4 for 2 or 4days. Tacrolimus was used for prophylaxis of graft-vs-host disease (GVHD). The median infused total cell dose was 2.78 x 107/kg (range, 1.94-5.53 x 107/kg). Results: 24 patients achieved primary neutrophil engraftment after a median of 22 days(range, 14-47). 12 of 24 patients with engraftment achieved complete donor-type chimerism by day 100. 11 patients developed grade II to IV acute GVHD, and 9 developed chronic GVHD. Transplant-related mortality within 100 days occurred in 11 of 45 patients. 9 patients were alive in remission at median follow up of 27 months (range, 2-117). The estimated 1-year probability of overall survival was 27.2% (95% CI 15.0-41.0). 6 of 45 patients were ≥ 70 years old, and all of them died within 100 days. The overall survival probabilities of patients aged 65-69 were found to be similar to younger patients. Conclusions: These data suggest that RI-CBT is a feasible option for patients under 70 years of age with advanced hematologic malignancies who lack an HLA-matched donor.
New diagnostic algorithm of acute kidney injury in cirrhosis that includes categorization of stage 1 and assessment of urine NGAL. Relevance for the differential diagnosis and clinical outcomes
Authors: P. Huelin, C. Elia, E. Solà, C. Solé, R. Moreira, M. Carol, N. Fabrelles, À. Risso, S. Albertos, E. Glavin, G. de Prada, E. Pose, I. Graupera, M. Morales, P. Ginès
Journal: Journal of Hepatology (2017)
Influence of marital status on tumor characteristics and survival in male breast cancer.
Authors: Shourya Tadisina, Ujwala Koduru, Charles Chacko, Oyebimpe Adekolujo, Rukevwe Ehwarieme, Joseph Ramzy, Madan L. Arora, Jill Gernand, Radhika Kakarala, Orimisan Samuel Adekolujo, Susan Smith
Journal: Journal of Clinical Oncology (2015)

1064 Background: The effect of marital status (MS) on survival varies according to cancer type and gender. To our knowledge there has been no report on the impact of MS on survival in male breast cancer (MBC). This study aims to determine the influence of MS on tumor characteristics at diagnosis and 5-year cancer specific survival (CSS) in MBC using the SEER database. Methods: We included patients (pts) with MBC ≥ 18 years of age in the SEER database from 1990 to 2011. Pts with unknown MS or survival data were excluded. Marital status was classified as married and unmarried (including single, divorced, separated, widowed and domestic partners). Kaplan-Meier method was used to estimate the 5-year CSS. Multivariate regression models were used to determine the independent covariates of cancer specific mortality and metastatic disease (stage IV) at diagnosis (Cox and logistic respectively). Results: We included 3,761 pts; 2,647 (70.4%) were married. Mean age was 64.9 years with no significant difference between the married and unmarried. Unmarried pts were more often diagnosed with advanced MBC (Stage III & IV) compared to married pts (33.3% vs. 22.1%, p<0.0001) but there was no significant difference in hormone receptor status, histologic grade or subtype. Unmarried pts were significantly less likely to undergo surgery compared to married pts (92.4% vs. 96.7%, p<0.0001). Overall unmarried pts with stage II, III & IV MBC have significantly worse 5-year CSS compared to married (Table). The survival difference between the two groups was significant only in MBC diagnosed after the year 1999. On multivariate analysis being unmarried was associated with increased hazard of death (HR=1.44, p<0.0001) and increased likelihood of metastatic disease at diagnosis (OR=1.95, p<0.0001). Conclusions: It is known that males with breast cancer (BC) have worse survival compared to females. Our study showed that unmarried males with BC are at an even greater risk for advanced disease at diagnosis and poorer outcomes compared to married males. 5-year cancer specific survival. Stage Married Unmarried p-value* I 98% 96% 0.685 II 91% 86% 0.049 III 76% 71% 0.038 IV 31% 12% 0.002 Overall 88% 77% < 0.0001 *Log rank test.
Results of a feasibility analysis of quality indicators for outpatient cancer care.
Authors: Kerstin Hermes, Walter Baumann, Andreas Zimmermann, Stephan H. Schmitz
Journal: Journal of Clinical Oncology (2013)

6623 Background: Quality indicators are increasingly used for measuring quality of care, for internal quality assurance, confidential benchmarking processes and anonymous quality reporting. The WINHO quality indicators project aims to develop and examine process quality measures for outpatient cancer care in Germany. This project is fully funded by the German Cancer Aid (Deutsche Krebshilfe). Currently, a set of 46 quality indicators exists. To gain better insights into what data can be retrieved from patient records and documentation systems in oncology practices, a feasibility analysis was conducted prior to data collection. Methods: 2176 questionnaires focusing on different aspects of the feasibility of quality indicators were sent to 295 doctors of WINHO partner practices. 1089 questionnaires were answered. Hence, for each of the 46 WINHO quality indicators 20 to 27 answers are available. Results: Although about 80% of the data required for the indicators are documented in patient charts, less than 30% of the data can be retrieved electronically. Particularly, data for indicators of the quality of pain management, holistic and palliative care often cannot be retrieved easily. By contrast, data on basal documentation, therapy planning and implementation are easier to obtain from patient charts. As a result, these indicators experience better evaluations by the office-based oncologists regarding frequency of occurrence, acceptance and reliability. However, high standard deviations show that documentation habits vary considerably within the group of office-based cancer specialists. Conclusions: Despite the large amount of data documented by oncologists in everyday practice, the information required to measure quality of care with indicators is complicated by low retrievability of data. Facilitating improved documentation and IT systems in oncology practices would ease the collection and examination of the rich information documented by office-based oncologists.
Platelet Malondialdehyde Production, Erythrocyte And Platelet Fatty-Acid Cell-Membrane Composition In Non-Dialyzed And Dialyzed Uremic Patients
Authors: M. Azzini, D. Girelli, O. Olivieri, P. Guarini, M. T. Trevisan, A. Lupo, P. Bernich, G. Panzetta, R. Corrocher
Journal: Kidney International (1993)
A prospective study of breast cancer subtypes in a cohort of Latin American patients.
Authors: Alejandro Yabar, Rosa Melendez, Silvia Munoz, Hugo Deneo, Jimena Freire, Viviana Dominguez, Hedwig Schmidt, Fiorella Pando, Angelo Storace
Journal: Journal of Clinical Oncology (2015)

e12615 Background: Although Ki-67 is important in sub classifying luminal breast cancers, many reports from Latin American Countries does not include the evaluation of this marker in the immunohistochemistry panel. Our aim was to describe expression of ER, PR, HER2 and the frequency of breast cancer phenotypes identified for a panel of immunohistochemistry biomarkers, including Ki-67, in a cohort of Latin American women. Methods: We enrolled in a prospective study 580 patients from 4 centers in Lima (Peru) and one in Montevideo (Uruguay). Breast cancer phenotypes were classified according the expressions of ER, PR, HER2 and Ki-67. In addition, SISH analysis was used in cases with HER2 equivocal status (HER2 2+). Results: The ER was positive in 65% (n = 377) of cases, the PR in 50% (n = 203), 79.1% (n = 459) were HER2 negative, 19.8% (n = 115) were HER2 positive and 1% (n = 6) were equivocal. In regard to Ki-67 expression, 55.3% (n = 321) had an expression ≤ 14% and 44.7% (n = 259) had an expression > 14%. Subtypes were luminal A, 31.9% (n = 183); luminal B, 35% (n = 201); HER2, 12.1% (n = 70) and triple negative, 20.9% (n = 120). When Ki-67 is not included in the panel, frequency of luminal A is 41.1% and luminal B is 25.8%. Conclusions: Luminal B tumors were most frequent while frequency of luminal A tumors are overestimated if Ki-67 is not evaluated. Frequency of triple negative and HER2 tumors were similar to described previously for Latin American population
Intensive care in thoracic oncology
Authors: Anne-Pascale Meert, Bogdan Grigoriu, Marc Licker, Paul E. Van Schil, Thierry Berghmans
Journal: European Respiratory Journal (2017)

The admission of lung cancer patients to intensive care is related to postprocedural/postoperative care and medical complications due to cancer or its treatment, but is also related to acute organ failure not directly related to cancer. Despite careful preoperative risk management and the use of modern surgical and anaesthetic techniques, thoracic surgery remains associated with high morbidity, related to the extent of resection and specific comorbidities. Fast-tracking processes with timely recognition and treatment of complications favourably influence patient outcome. Postoperative preventive and therapeutic management has to be carefully planned in order to reduce postoperative morbidity and mortality. For patients with severe complications, intensive care unit (ICU) mortality rate ranges from 13% to 47%, and hospital mortality ranges from 24% to 65%. Common predictors of in-hospital mortality are severity scores, number of failing organs, general condition, respiratory distress and the need for mechanical ventilation or vasopressors. When considering long-term survival after discharge, cancer-related parameters retain their prognostic value. Thoracic surgeons, anesthesiologists, pneumologists, intensivists and oncologists need to develop close and confident partnerships aimed at implementing evidence-based patient care, securing clinical pathways for patient management while promoting education, research and innovation. The final decision on admitting a patient with lung to the ICU should be taken in close partnership between this medical team and the patient and his or her relatives.